Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing
Executive Summary
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.
You may also be interested in...
Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA
Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.
Gene Therapy Libmeldy Undergoes Cross-Country HTA In Europe
Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.
Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.